Financial Performance - Net profit attributable to shareholders decreased by 23.21% to CNY 34,861,755.22 for Q1 2024, down from CNY 45,399,312.04 in Q1 2023[12] - Operating revenue for Q1 2024 was CNY 137,674,996.19, representing a decline of 21.40% compared to CNY 175,152,565.78 in the same period last year[12] - The weighted average return on net assets based on net profit attributable to shareholders was 3.02% for Q1 2024, down from 4.09% in Q1 2023[12] - Total operating revenue for Q1 2024 was CNY 137,674,996.19, a decrease from CNY 175,152,565.78 in Q1 2023, representing a decline of approximately 21.5%[40] - Total operating costs for Q1 2024 were CNY 97,935,912.87, down from CNY 121,282,349.06 in Q1 2023, indicating a reduction of about 19.2%[40] - The net profit for Q1 2024 was CNY 1,260,452.45, an increase from CNY 912,375.25 in Q1 2023, representing a growth of approximately 38%[43] - The total profit for Q1 2024 was CNY 1,735,801.74, an increase from CNY 1,256,211.59 in Q1 2023, representing a growth of approximately 38%[43] - The basic earnings per share for Q1 2024 was CNY 0.0817, down from CNY 0.1063 in Q1 2023, reflecting a decrease of about 23%[42] Cash Flow - The net cash flow from operating activities decreased by 19.86% to CNY 19,833,649.82 in Q1 2024, down from CNY 24,748,327.96 in Q1 2023[12] - Cash received from operating activities increased by 1,684,260.57 yuan, up 168.24% compared to the previous period, mainly due to an increase in interest income[15] - Cash paid for various taxes decreased by 10,316,710.10 yuan, down 46.90%, primarily due to the expiration of tax deferral policies for small and micro enterprises[15] - Cash paid for other operating activities decreased by 3,768,800 yuan, down 42.07%, mainly due to a reduction in transportation costs[15] - The cash inflow from operating activities in Q1 2024 was CNY 115,291,036.73, compared to CNY 140,961,929.11 in Q1 2023, a decrease of approximately 18%[45] - The cash outflow from operating activities in Q1 2024 was CNY 95,457,386.91, down from CNY 116,213,601.15 in Q1 2023, indicating a reduction of about 18%[45] - The total cash outflow from operating activities in Q1 2024 was 1,855,899.69, down from 3,510,686.41 in Q1 2023, reflecting a decrease of approximately 47.3%[48] - The cash flow from operating activities netted a total of 1,435,065.57 in Q1 2024, indicating a positive trend in operational cash generation[47] Assets and Liabilities - Total assets increased by 1.75% to CNY 1,350,576,245.07 as of March 31, 2024, compared to CNY 1,327,313,296.09 at the end of 2023[12] - The company's debt-to-asset ratio decreased to 7.69% in Q1 2024 from 8.87% at the end of 2023[12] - Total liabilities decreased to CNY 103,905,317.35 as of March 31, 2024, from CNY 117,735,441.12 at the end of 2023, a reduction of approximately 11.8%[36] - The company's total equity increased to CNY 1,246,670,927.72 as of March 31, 2024, compared to CNY 1,209,577,854.97 at the end of 2023, representing an increase of about 3.1%[36] - The total liabilities to equity ratio improved to approximately 8.33 as of March 31, 2024, down from 9.73 at the end of 2023, indicating a strengthening of the company's financial position[36] Investments and Expenses - Construction in progress increased by 138.00% to CNY 23,454,152.42, primarily due to investments in new production projects[13] - Research and development expenses increased to CNY 7,116,442.26 in Q1 2024, compared to CNY 5,774,630.02 in Q1 2023, reflecting a growth of approximately 23.2%[40] - The company reported a fair value gain of CNY 594,616.44 in Q1 2024, compared to CNY 694,750.68 in Q1 2023, reflecting a decrease of about 14%[43] - The company experienced a credit impairment loss of CNY -455.00 in Q1 2024, compared to CNY 410.00 in Q1 2023, indicating a worsening in credit quality[43] Shareholder Information - The total number of ordinary shares at the end of the period was 426,918,340, with 99.9517% being unrestricted shares[20] - The largest shareholder, Jinghua Pharmaceutical Group Co., Ltd., holds 308,724,340 shares, accounting for 72.3146% of the total shares[22] - The company did not have any pledged or judicially frozen shares during the reporting period[23] Other Financial Metrics - The company reported a total of CNY 24,461,685.30 in assets under pledge or mortgage, accounting for 1.81% of total assets[30] - The company executed daily related transactions with a total expected amount of CNY 15 million for raw materials, but only CNY 25,530.98 was incurred in the reporting period[29] - The company recorded CNY 1,594,876.10 in sales of products and services against an expected amount of CNY 40 million for the year[29] - The company's cash and cash equivalents increased to CNY 513,461,081.25 as of March 31, 2024, compared to CNY 505,949,141.18 at the end of 2023[34] - The company’s accounts receivable rose to CNY 42,131,543.54 from CNY 34,237,921.14, indicating a growth in credit sales[34] - The company’s fixed assets decreased to CNY 341,639,869.66 from CNY 352,114,874.54, reflecting asset depreciation[34] - The company’s inventory stood at CNY 146,378,353.94, slightly up from CNY 145,993,690.74, indicating stable stock levels[34]

江苏森萱医药股份有限公司 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2024 年 4 月 28 日 2.会议召开地点：江苏省南通市崇川区青年中路 198 号国城广场 A 幢 21 楼会议 室 3.会议召开方式：以现场加通讯方式召开 证券代码：830946 证券简称：森萱医药 公告编号：2024-033 江苏森萱医药股份有限公司 第四届监事会第三次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 具体内容详见公司于同日在北京证券交易所信息披露平台（www.bse.cn）披 露的《2023 年第一季度报告》（公告编号：2024-031）。 2.议案表决结果：同意 3 票；反对 0 票；弃权 0 票。 3.回避表决情况 4.发出监事会会议通知的时间和方式：2024 年 4 月 19 日以书面、邮件等方式发 出 5.会议主持人：秦建 6.召开情况合法、合规、合章程性说明： 本次会议的召集、召开符合《公司法》、《公司章程》的相关规定。 （二）会议出席情况 会议应出席监事 3 人，出 ...

江苏森萱医药股份有限公司 2023 年年度报告说明会预告 暨落实"提质守信重回报"行动公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 说明会类型 江苏森萱医药股份有限公司（以下简称"公司"）于 2024 年 4 月 18 日在北 京证券交易所官网（www.bse.cn）披露了《2023 年年度报告》（公告编号： 2024-004）,为方便广大投资者更深入了解公司 2023 年年度经营业绩的具体情 况，进一步落实证监会"提质守信重回报"行动，加强与投资者的互动交流，公 司拟召开 2023 年年度报告网上业绩说明会，广泛听取投资者的意见和建议。 二、 说明会召开的时间、地点 （一）会议召开时间：2024 年 5 月 10 日 15：00-17：00。 （二）会议召开地点 证券代码：830946 证券简称：森萱医药 公告编号：2024-034 江苏森萱医药股份有限公司 江苏森萱医药股份有限公司 四、 投资者参加方式 本次说明会采用网络方式召开。 为充分尊重投资者、提升交流的针对性，现就公司 202 ...

江苏森萱医药股份有限公司 二、审议及表决情况 公司于 2024 年 4 月 16 日召开第四届董事会第二次会议、第四届监事会第二 次会议，会议审议并通过了《关于向商业银行申请授信并贷款的议案》，该议案 尚需提交 2023 年年度股东大会审议。具体内容详见公司于同日在北京证券交易 所官方信息披露平台(www.bse.cn)上披露的《第四届董事会第二次会议决议公告》 （公告编号：2024-006）、《第四届监事会第二次会议决议公告》（公告编号：2024- 007）。 证券代码：830946 证券简称：森萱医药 公告编号：2024-022 江苏森萱医药股份有限公司 关于向商业银行申请授信并贷款的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担 个别及连带法律责任。 一、申请授信的基本情况 因公司经营需要，结合公司各子公司当前发展计划及未来资金需求状况，提 升各子公司自身的融资能力，公司各子公司拟向商业银行申请授信并贷款额度不 超过 5 亿元（贷款期限不限，年贷款利率参考市场价格确定）。在以上贷款额度 范围内，授权公司经营层代表 ...

江苏森萱医药股份有限公司 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开基本情况 （一）股东大会届次 本次会议为 2023 年年度股东大会。 （二）召集人 本次股东大会的召集人为董事会。 证券代码：830946 证券简称：森萱医药 公告编号：2024-026 江苏森萱医药股份有限公司 关于召开 2023 年年度股东大会通知公告（提供网络投票） 2024 年 4 月 16 日，公司第四届董事会第二次会议审议通过《关于审议<2023 年度董事会工作报告>的议案》、《关于审议<2023 年度独立董事述职报告>的议 案》、《关于审议<2023 年年度报告>及<2023 年年度报告摘要>的议案》、《关于审 议<2023 年度财务决算报告>的议案》、《关于审议<2024 年度财务预算报告>的议 案》、《关于审议<2023 年度利润分配预案>的议案》、《关于公司董事、高级管理 人员 2023 年度薪酬考核兑现的议案》、《关于确定 2024 年度独立董事津贴的议 案》、《关于使用自有闲置资金进行现金管理的 ...

2023 年度独立董事述职报告（任勇） 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《公司法》、《证券法》、《北京证券交易所股票上市规则（试行）》、《上 市公司独立董事管理办法》、《北京证券交易所上市公司持续监管指引第 1 号—— 独立董事》等法律法规及《公司章程》、《独立董事工作细则》的规定，作为江苏 森萱医药股份有限公司（以下简称"公司"）的独立董事，忠实、勤勉、尽责地 履行独立董事职责，积极出席相关会议，认真审议董事会各项议案，充分发挥独 立董事的独立性和专业性作用，切实维护了公司股东尤其是中小股东的利益。现 将 2023 年度履职情况作出如下报告： 一、独立董事基本情况及独立性情况 任勇，男，1959 年生，中国国籍，无境外永久居留权，中国药科大学药物 化学博士学位。1975 年 9 月至 1978 年 3 月，为湖北省远安县茅坪乡老观村知青 点知青；1978 年 3 月至 1980 年 1 月，于湖北三峡大学化学系学习；1980 年 2 月至 1988 年 8 月，于湖北省宜昌市工业技工学，任校助教、讲师；1 ...

Financial Performance - Operating revenue for 2023 was CNY 1,603,773,580, a decrease of 5.57% from CNY 1,698,113,210 in 2022[96] - Net profit for 2023 was CNY 80,283,981, a decrease of 12.16% compared to CNY 91,476,895 in 2022[96] - Investment income for 2023 was CNY 75,552,819, down 12.19% from CNY 86,110,152 in 2022[96] - The company's total revenue for 2023 was 589,560,024.01 yuan, with raw material sales contributing 339,935,892.96 yuan, accounting for 57.66% of total revenue[116] - The net profit attributable to shareholders of the listed company was ¥134,523,788.78, down 16.22% from ¥160,565,366.42 in the previous year[146] - The gross profit margin for 2023 was 43.01%, compared to 44.85% in 2022, indicating a decline in profitability[146] - The net profit after deducting non-recurring gains and losses was ¥128,120,137.91, a decrease of 14.57% from ¥149,963,922.80 in 2022[146] - The basic earnings per share for 2023 was ¥0.3151, down 16.22% from ¥0.3761 in the previous year[146] - The revenue growth rate for the company was -5.46%, while the net profit growth rate was -15.94%[148] Cash Flow and Assets - Cash flow from operating activities totaled CNY 581,588,655, an increase of 4.27% from CNY 558,090,764 in 2022[97] - Cash flow from investing activities showed a net outflow of CNY 154,000,000, compared to CNY 150,260,853 in 2022[100] - Cash flow from financing activities resulted in a net outflow of CNY 86,233,668, compared to CNY 77,625,118 in 2022[100] - The company's total assets at the end of 2023 were CNY 1,156,702,540, reflecting a stable financial position[101] - The total assets of the company amounted to approximately ¥829.26 million, a decrease from ¥836.88 million in the previous period, reflecting a decline of about 0.75%[69] - The total current assets increased to approximately ¥383.99 million from ¥379.24 million, representing a growth of about 1.98%[69] - Long-term equity investments rose to approximately ¥443.55 million, up from ¥410.55 million, indicating an increase of about 8.03%[69] - The company reported a significant decrease in fixed assets, which fell to approximately ¥262.17 million from ¥356.22 million, a decline of about 26.4%[69] - Cash and cash equivalents at the end of 2023 amounted to CNY 505,949,141.18, representing 38.12% of total assets, an increase of 4.74% from 37.34% in 2022[196] Research and Development - The company reported a total R&D investment of approximately ¥11.58 million for the current period, with cumulative R&D investment reaching ¥13.06 million[25] - The company achieved breakthroughs in the R&D of raw materials such as Ritonavir and Indocyanine Green, improving overall yield, purity, and cost significantly[24] - The company’s R&D projects include the preparation of Ritonavir raw materials, with ongoing pilot testing stages for several projects[25] - Research and development expenditures are expected to rise as the company invests in innovative technologies and product enhancements[95] - The company has developed and industrialized generic drugs, supporting the upgrade of products through the consistency evaluation of quality and efficacy since 2015[33] Corporate Governance - The company has established a comprehensive governance structure, including a board of directors and various committees, to enhance corporate governance and decision-making processes[73] - The audit committee held five meetings during the reporting period to review key financial reports and related transactions, ensuring compliance and oversight[78] - The company has implemented a performance evaluation system for senior management, linking compensation to both monthly salary and annual performance outcomes[82] - The company has revised its governance policies in accordance with regulatory requirements, ensuring transparency and accountability in its operations[76] - The company has established a comprehensive investor relations management system to facilitate communication with investors[48] Market Presence and Sales - The company primarily adopts a dual sales model focusing on domestic and international markets, with major sales regions including Europe, America, and Asia[34] - The company has a clear target customer base in domestic sales, directly selling products to pharmaceutical companies and large medical distribution enterprises[34] - The company is focusing on expanding its market presence and exploring potential mergers and acquisitions to drive future growth[95] - New product development initiatives are underway, aimed at enhancing the company's competitive edge in the market[95] Environmental and Safety Standards - The company has implemented a series of environmental protection measures, including obtaining the Environmental Impact Assessment approval and the Pollution Discharge Permit[27] - The company emphasizes the importance of safety and environmental standards, having established a comprehensive safety management system and regular employee training[27] Employee and Management - The total number of employees decreased from 655 to 644 during the reporting period[16] - The company has not experienced any changes in key management positions, except for independent directors[11] - The company has a total of 3 PhD holders and 8 Master's degree holders among its employees[16] Financial Ratios and Metrics - The current ratio was 8.40, indicating strong liquidity compared to the previous year's 6.38[167] - The interest coverage ratio was 175.45, down from 299.04 in the previous year, indicating a decrease in earnings relative to interest expenses[167] - The weighted average return on equity based on net profit attributable to shareholders was 12.18%, down from 15.57% in 2022[146] - The weighted average return on net assets (after deducting non-recurring gains and losses) was 11.60% for 2023, up from 11.50% in the previous estimate[187] Government Support and Recognition - The company has received significant government research grants and subsidies, enhancing its R&D capabilities[39] - The company was recognized as a "green leading enterprise" and "provincial green factory" in December 2023[133] - The company’s subsidiary, Nantong Senxuan, received the national "specialized and innovative" small giant enterprise title in December 2023[130]

江苏森萱医药股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《公司法》、《证券法》、《北京证券交易所股票上市规则（试行）》、《上 市公司独立董事管理办法》、《北京证券交易所上市公司持续监管指引第 1 号—— 独立董事》等法律法规及《公司章程》、《独立董事工作细则》的规定，作为江苏 森萱医药股份有限公司（以下简称"公司"）的独立董事，忠实、勤勉、尽责地 履行独立董事职责，积极出席相关会议，认真审议董事会各项议案，充分发挥独 立董事的独立性和专业性作用，切实维护了公司股东尤其是中小股东的利益。现 将 2023 年度履职情况作出如下报告： 一、独立董事基本情况及独立性情况 沈小燕，女，1974 年 5 月出生，中国国籍，无境外永久居留权，南京大学 会计学博士学位。1997 年 7 月至 2005 年 5 月，于南通师范学院，任助教、讲师； 2005 年 5 月至 2016 年 7 月，于南通大学商学院，任讲师、副教授；2016 年 8 月至 2018 年 12 月，于南通大学商学院，任副院长、教授；2019 年 9 ...

江苏森萱医药股份有限公司 证券代码：830946 证券简称：森萱医药 公告编号：2024-021 江苏森萱医药股份有限公司 使用闲置募投项目资金进行现金管理的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、募集资金基本情况 2020 年 7 月 27 日，江苏森萱医药股份有限公司发行普通股 60,000,000 股， 发行方式为公开发行，发行价格为5.40元/股，募集资金总额为324,000,000元， 实际募集资金净额为 300,084,000 元，到账时间为 2020 年 7 月 16 日。 二、募集资金使用情况 （一）募集资金使用情况和存储情况 截至 2023 年 12 月 31 日，公司上述发行股份的募集资金使用情况具体如下： | 序号 | 募集资金 | | 实施 | | 募集资金计划 投资总额（调 | 累计投入募集 资金金额 | 投入进度 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | ...

江苏森萱医药股份有限公司 证券代码：830946 证券简称：森萱医药 公告编号：2024-016 江苏森萱医药股份有限公司 关于募集资金 2023 年度存放与使用情况的专项报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、募集资金基本情况 （一）2020 年公开发行募集资金基本情况 经中国证券监督管理委员会《关于核准江苏森萱医药股份有限公司向不特定 合格投资者公开发行股票的批复》（证监许可[2020]1302 号），核准公司向不 特定合格投资者公开发行不超过 9,000 万股新股，公司第三届董事会第二次会议 在股东大会的授权范围内确定最终发行股份为 6,000 万股，经询价后和主办券商 开源证券股份有限公司确定本次发行价格人民币 5.40 元/股，募集资金总额人民 币 32,400.00 万元，公司募集资金扣除需支付的承销、保荐费用 2,106.00 万元 后的 30,294.00 万元已于 2020 年 7 月 16 日全部存入公司开立的江苏张家港农村 商业银行股份有限公司南通分行的 8020 ...